Patents by Inventor Teresa M. Foy
Teresa M. Foy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20030236209Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.Type: ApplicationFiled: December 4, 2002Publication date: December 25, 2003Applicant: Corixa CorporationInventors: Teresa M. Foy, Andria McNabb, Yoshihiro Watanabe, Steven G. Reed, Tongtong Wang
-
Publication number: 20030157089Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.Type: ApplicationFiled: May 9, 2002Publication date: August 21, 2003Applicant: Corixa CorporationInventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Yuqiu Jiang, Robert A. Henderson, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day, Thomas S. Vedvick, Darrick Carter, Samuel X. Li, Aijun Wang, Yasir A.W. Skeiky, William T. Hepler, John Hural, Patricia D. McNeill, Raymond L. Houghton, Carlota Vinals y de Bassols, Teresa M. Foy, Yoshihiro Watanabe, Madeleine Joy Meagher, Ta Deng
-
Publication number: 20030138438Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.Type: ApplicationFiled: April 5, 2002Publication date: July 24, 2003Applicant: Corixa CorporationInventors: Barbara Mericle, Gary R. Fanger, Thomas S. Vedvick, Darrick Carter, Yoshihiro Watanabe, Robert A. Henderson, Michael D. Kalos, A. Gregory Spies, Teresa M. Foy, Liqun Fan, Tongtong Wang
-
Publication number: 20030125536Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer.Type: ApplicationFiled: August 2, 2002Publication date: July 3, 2003Applicant: Corixa CorporationInventors: Gary R. Fanger, Shannon Kathleen Hirst, Davin C. Dillon, Teresa M. Foy, Raymond L. Houghton, David H. Persing, Michael D. Kalos
-
Publication number: 20030064947Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.Type: ApplicationFiled: November 30, 2001Publication date: April 3, 2003Applicant: Corixa CorporationInventors: Tongtong Wang, Aijun Wang, Yasir A. W. Skeiky, Samuel X. Li, Michael D. Kalos, Robert A. Henderson, Patricia D. McNeill, Neil Fanger, Marc W. Retter, Margarita Durham, Gary R. Fanger, Thomas S. Vedvick, Darrick Carter, Yoshihiro Watanabe, David W. Peckham, Feng Cai, Teresa M. Foy
-
Publication number: 20030045468Abstract: Compositions and methods for the therapy, diagnosis and monitoring of breast cancer are disclosed. Compositions may comprise one or more mammaglobin epitopes, or antibodies or T cells thereto, and may be used, for example, for the prevention and treatment of breast cancer. Diagnostic methods based on detecting the presence of mammaglobin epitopes, or antibodies or T cells thereto, in a sample are also provided. Also provided are methods for detecting RNA encoding mammaglobin in patient blood or fractions thereof. These methods may be used to detect and/or monitor the progression of breast cancer.Type: ApplicationFiled: January 8, 2002Publication date: March 6, 2003Applicant: Corixa CorporationInventors: Steven P. Fling, Teresa M. Foy, Jonathan D. Clapper, Aijun Wang, Jeffrey C. Johnson, Patricia D. McNeill, R. Alec Sutherland
-
Publication number: 20020192763Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.Type: ApplicationFiled: June 29, 2001Publication date: December 19, 2002Inventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Yuqiu Jiang, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day, Thomas S. Vedvick, Darrick Carter, Samuel X. Li, Aijun Wang, Yasir A. W. Skeiky, William T. Hepler, Robert A. Henderson, John Hural, Patricia D. McNeill, Raymond L. Houghton, Carlota Vinals y de Bassols, Teresa M. Foy
-
Publication number: 20020193296Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.Type: ApplicationFiled: June 29, 2001Publication date: December 19, 2002Inventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Yuqiu Jiang, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day, Thomas S. Vedvick, Darrick Carter, Samuel X. Li, Aijun Wang, Yasir A. W. Skeiky, William T. Hepler, Robert A. Henderson, John Hural, Patricia D. McNeill, Raymond L. Houghton, Carlota Vinals y de Bassols, Teresa M. Foy
-
Publication number: 20020193329Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly Her-2/neu-associated cancers, are disclosed. Illustrative compositions comprise one or more Her-2/neu polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of Her-2/neu-associated malignancies.Type: ApplicationFiled: August 14, 2001Publication date: December 19, 2002Applicant: Corixa CorporationInventors: Susan Hand-Zimmermann, Martin A. Cheever, Teresa M. Foy, Michael J. Lodes, Michael D. Kalos, Patricia D. McNeill, Thomas S. Vedvick
-
Publication number: 20020187135Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.Type: ApplicationFiled: October 1, 1998Publication date: December 12, 2002Inventors: RANDOLPH J. NOELLE, TERESA M. FOY, FIONA H. DURIE
-
Publication number: 20020183251Abstract: Compositions and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Illustrative compositions comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.Type: ApplicationFiled: December 10, 2001Publication date: December 5, 2002Applicant: Corixa CorporationInventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Yuqiu Jiang, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day, Thomas S. Vedvick, Darrick Carter, Samuel X. Li, Aijun Wang, Yasir A.W. Skeiky, William T. Hepler, Robert A. Henderson, John Hural, Patricia D. McNeill, Raymond L. Houghton, Carlota Vinals y de Bassols, Teresa M. Foy, Yoshihiro Watanabe, Madeleine Joy Meagher
-
Publication number: 20020082216Abstract: Compositions and methods for the therapy, diagnosis and monitoring of breast cancer are disclosed. Compositions may comprise one or more mammaglobin epitopes, or antibodies or T cells thereto, and may be used, for example, for the prevention and treatment of breast cancer. Diagnostic methods based on detecting the presence of mammaglobin epitopes, or antibodies or T cells thereto, in a sample are also provided. Also provided are methods for detecting RNA encoding mammaglobin in patient blood or fractions thereof. These methods may be used to detect and/or monitor the progression of breast cancer.Type: ApplicationFiled: January 8, 2001Publication date: June 27, 2002Inventors: Gary R. Fanger, Teresa M. Foy, Raymond L. Houghton, Steven G. Reed
-
Patent number: 6312692Abstract: A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.Type: GrantFiled: April 30, 1998Date of Patent: November 6, 2001Assignees: Trustees of Dartmouth College, Bristol-Myers Squibb CompanyInventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter
-
Patent number: 5942229Abstract: Methods of suppressing a humoral immune response to a thymus-dependent (TD) antigen are disclosed. The methods involve administering to a subject a TD antigen with an antagonist of a molecule which mediates contact-dependent helper effector functions. In a preferred embodiment, the antagonist is an antagonist of gp39. Primary and secondary humoral immune responses can be suppressed and suppression is prolonged.Type: GrantFiled: June 7, 1995Date of Patent: August 24, 1999Assignee: Trustees of Dartmouth CollegeInventors: Randolph J. Noelle, Teresa M. Foy
-
Patent number: 5876718Abstract: Antibodies that bind a protein gp39 (also referred to as CD40 ligand) are disclosed. Preferably, the antibodies are monoclonal antibodies of an IgG1 isotype and bind human gp39. In a preferred embodiment, an antibody of the invention binds an epitope recognized by a monoclonal antibody 24-31, produced by a hybridoma 24-31 (ATTC Accession No. HB11712) or binds an epitope recognized by a monoclonal antibody 89-76, produced by a hybridoma 89-76 (ATCC Accession No. HB 11713). Pharmaceutical compositions comprising the antibodies of the invention are also disclosed. The antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses and for inducing T cell tolerance. Nucleic acid molecules encoding anti-gp39 antibodies, or portions thereof, as well as expression vectors and host cells incorporating said nucleic acid molecules, are also encompassed by the invention.Type: GrantFiled: March 27, 1998Date of Patent: March 2, 1999Assignees: Trustees of Dartmouth College, Bristol-Myers Squibb CompanyInventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter
-
Patent number: 5869049Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.Type: GrantFiled: April 25, 1994Date of Patent: February 9, 1999Assignees: Trustees of Dartmouth College, University of Massachusetts Medical CenterInventors: Randolph J. Noelle, Teresa M. Foy, Fiona H. Durie, David C. Parker, Dale L. Greiner, Aldo A. Rossini, John P. Mordes
-
Patent number: 5747037Abstract: Antibodies that bind a protein gp39 (also referred to as CD40 ligand) are disclosed. Preferably, the antibodies are monoclonal antibodies of an IgG1 isotype and bind human gp39. In a preferred embodiment, an antibody of the invention binds an epitope recognized by a monoclonal antibody 24-31, produced by a hybridoma 24-31 (ATTC Accession No. HB11712) or binds an epitope recognized by a monoclonal antibody 89-76, produced by a hybridoma 89-76 (ATCC Accession No.HB11713). Pharmaceutical compositions comprising the antibodies of the invention are also disclosed. The antibodies of the invention are useful for inhibiting B cell proliferation and differentiation, T cell responses and for inducing T cell tolerance. Nucleic acid molecules encoding anti-gp39 antibodies, or portions thereof, as well as expression vectors and host cells incorporating said nucleic acid molecules, are also encompassed by the invention.Type: GrantFiled: June 7, 1995Date of Patent: May 5, 1998Assignees: Bristol-Myers Squibb Company, Trustees of Dartmouth CollegeInventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter